Amphastar Pharmaceuticals Reports Revenues of $55.9 Million for the Fourth Quarter Ended December 31, 2014
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Amphastar Pharmaceuticals (AMPH) PT Raised to $18 at Jefferies
March 25, 2015 7:43 AM EDTJefferies analyst David Steinberg reiterated a Buy rating and boosted his price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $18.00 (from $15.00) following a narrower Q4 loss.
Steinberg commented, "AMPH Q4 EPS of -$0.03 was +0.03 ahead of our est, with higher op expenses... More
Amphastar Pharmaceuticals (AMPH) PT Raised to $19 at Piper Jaffray
March 25, 2015 6:58 AM EDTPiper Jaffray analyst David Amsellem reiterated an Overweight-rating and boosted his price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $19.00 (from $16.00) following solid execution in Q4.
Amsellem commented, "Amphastar reported a 4Q14 net loss per share of ($0.03) on revenues of $56M, compared to the Street estimates of ($0.07) and... More
Amphastar Pharma (AMPH) Tops Q4 EPS by 7c
March 24, 2015 4:03 PM EDTAmphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of ($0.03), $0.07 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $55.9 million, versus $54.9 million reported last year.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
... More